Business Wire

Kezzler Announces New CEO Thomas Körmendi

Del

Kezzler AS, a leader in serialization business services, today announced the appointment of Thomas Körmendi as the company’s new chief executive officer. Mr. Körmendi brings more than 20 years of relevant experience to the packaging and consumer goods industries.

“As we enter a tremendous growth period for Kezzler, the Board of Directors welcome Thomas’ deep international experience and leadership to Kezzler," said Arve Johansen, chairman of the Board. "In his role as CEO, he will be responsible for delivering against our strategic business plan and to build on the significant momentum the company is currently experiencing. His results-oriented approach and ability to think strategically will play a pivotal role in extending our track record of innovation, while helping us grow toward profitability in 2017.”

“I am very excited to join Kezzler as I believe their technology platform could become the backbone of global serializations strategies, whether that is with key packaging companies such as Amcor or among global consumer brands. The Kezzler product portfolio has been tested and proven in some of the most regulated industries in the world, including Pfizer’s Viagra and Roche’s key cancer products. A key differentiator from other serialization technologies is the fact that, at a fraction of the cost and data foot print of competing database systems, Kezzler’s encrypted technology solution connects products and people with the scalability and security never been seen before,” said Mr. Körmendi.

Mr. Körmendi has worked extensively in the packaging industry and has an excellent grasp of the entire value chain of global companies, including supply chain issues and manufacturing operations. Most recently he was president and CEO at Relacom, a Swedish technology service company. Prior to that, he spent 18 years at Tetra Pak in roles of increasing responsibility. Tetra Pak is the world's leading food processing and packaging solutions company.

From 2006 to 2010 he served as vice president and head of North Europe, from 2003 to 2005 he was the managing director of Tetra Pak Turkey and Caucasus, and from 1998 to 2002 he served as managing director at Tetra Pak Hungary. He has also served as general manager for Tetra Pak in Bulgaria and vice president for Food, Fats and Oils at Tetra Laval in Sweden. He has held brand management positions at Procter & Gamble Nordic. Mr. Körmendi earned his Masters in Business from the Copenhagen Business School.

About Kezzler

Kezzler AS is a global leader in serializing products at the unit level. Headquartered in Oslo, Norway, the company has offices in the United States, India, the Netherlands and Austria.

Contact information

Kezzler AS
Paul Laland, +1-415-519-6610
VP Corporate Affairs
p.laland@kezzler.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

BearingPoint: How Firms Transform into Digital Superpowers22.2.2018 08:30Pressemelding

Digital disruption has left Europe’s leading companies struggling to sustain growth and competitive advantage. Groundbreaking new research reveals how European companies can learn from US digital superpowers to speed up adoption of business model innovation, drive new revenues and get greater value from their core business. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005241/en/ Diversifying business model Portfolio (Graphic: Business Wire) Today, firms that adopt a portfolio of business models which are asset light and include network effects are perceived by investors and the market as most likely to generate future growth. They therefore have a much higher market value in comparison to companies with traditional business models. Companies who diversified their business models improved their valuation in 2016 by 65% in comparison to those who maintained a mono-business model. Furthermore, between 2011-2016 they mana

Eli Global to Acquire Lead Generation Marketplace Finanzen22.2.2018 08:00Pressemelding

Eli Global LLC (“Eli”) today announced that an affiliate has entered into a definitive agreement to acquire finanzen.de AG and its subsidiaries (collectively, “Finanzen” or the “company”) from Blackfin Capital Partners (“Blackfin”) and Finanzen’s founders. Based in Berlin, Germany, Finanzen is the leading European online marketplace for retail customer leads in the finance and insurance sectors. The company connects lead generators such as online price comparison sites with lead buyers such as independent financial advisors and insurance agents. The company also acts as an online broker for certain insurance products. “Finanzen has done an impressive job creating a scalable technology platform poised to benefit from industry trends,” said George Luecke, global manager of Eli’s newly established insurance services portfolio and co-CEO of Global Bankers Insurance Group, which represents Eli’s life and annuity carrier division (“GBIG”). “We look forward to a long-term future with the comp

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage22.2.2018 06:00Pressemelding

Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO). CHAMPION is investigating whether Ferring’s proprietary and heat-stable carbetocin could offer a new solution to prevent excessive bleeding after childbirth (postpartum haemorrhage or PPH).2,3 Involving nearly 30,000 women in 10 countries, it is the largest clinical trial ever conducted in PPH.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221006496/en/ Each year, 14 million mothers are affected by PPH.4 As the leading direct cause of maternal mortality, 480,000 mothers died from PPH between 2003-09.1 Even when women survive, PPH can result in the need for serious medical interventions, including surgica

The Nippon Foundation: Project to Map Ocean Floor by 2030 Now Operational22.2.2018 05:00Pressemelding

The Nippon Foundation Chairman Yohei Sasakawa announced at a press conference today that The Nippon Foundation – GEBCO Seabed 2030 Project is now operational. The Project will realize Mr. Sasakawa’s vision of mapping the entire ocean floor by 2030. The Nippon Foundation has pledged US$2 million annually, and is calling for additional support from the global ocean community. Mr. Sasakawa noted, “The Nippon Foundation alone cannot achieve the objectives of this ambitious project. We will need the support of diverse stakeholders, including maritime corporations and technical experts. It is crucial that the ocean community comes together to achieve this goal”. He was joined by leading ocean-mapping experts, who emphasized that understanding the bathymetry of the global ocean is imperative for improving maritime navigation, and also for enhancing our ability to predict climate change and monitor marine biodiversity and resources. A comprehensive map of the seafloor will assist global effort

Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis21.2.2018 21:01Pressemelding

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical

Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00Pressemelding

ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized